Drug Trial Radar · NCT00306787
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
Last checked: Nov 19, 2026Latest source record: Jun 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,179
Actual
Start
Mar 2006
Primary completion
Feb 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
Conditions
- Genital Herpes
Interventions
FamciclovirDrug
Famciclovir 500 mg tablet
ValacyclovirDrug
Valacyclovir 500 mg capsule
Placebo matching famciclovirDrug
Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
Placebo matching valacyclovirDrug
Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Time to Healing of All Non-aborted Genital Herpes LesionsTime frame: 72 hours after initiation of study medication up to Day 20
Locations
66 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Novartis Investigative Site
Chandler, Arizona
Women's Health Research
Phoenix, Arizona
Quality of Life Medical & Research Center, LLC
Tucson, Arizona
Burke Pharmaceutical Research
Hot Springs, Arkansas
NEA Women's Clinic
Jonesboro, Arkansas
The Woman's Clinic
Little Rock, Arkansas
Providence Clinical Research
Burbank, California
Dermatology Research Associates
Los Angeles, California
Sacramento Research Medical Group
Sacramento, California
North California Research Corp.
Sacramento, California
Medical Center for Clinical Research
San Diego, California
Conant Research
San Francisco, California
Barbara Davis Center
Denver, Colorado
Cohen & Womack, P.C.
Lakewood, Colorado
Visions Clinical Research
Boynton Beach, Florida
Women's Medical Research Group, LLC
Clearwater, Florida
International Research Association LLC
Miami, Florida
Orlando Clinical Research Ctr.
Orlando, Florida
Avancia Research
Pembroke Pines, Florida
University Clinical Research, Inc.
Pembroke Pines, Florida
Palm Beach Research Center
West Palm Beach, Florida
Mount Vernon Clinical Research
Atlanta, Georgia
Medisphere Medical Research Center, LLC.
Evansville, Indiana
Indiana University Infectious Disease Research Group
Indianapolis, Indiana
Heartland Research Associates, LLC
Wichita, Kansas
Common Wealth Biomedical Research
Madisonville, Kentucky
SNBL Clinical Pharmacology Center
Baltimore, Maryland
Future Care Studies
Springfield, Massachusetts
Clayton Research Institute
St Louis, Missouri
Deaconess Billings Clinic Research Center
Billings, Montana
Heartland Clinical Research, Inc.
Omaha, Nebraska
UNC Clinical Research.
Raleigh, North Carolina
Hawthorne Medical Research, Inc.
Winston-Salem, North Carolina
Providence Health Partners-Center for Clinical Research
Dayton, Ohio
Lynne Health Science Institute
Oklahoma City, Oklahoma
Westover Heights Clinic
Portland, Oregon
Paddington Testing Co. Inc
Philadelphia, Pennsylvania
Magee Womens Hospital
Pittsburgh, Pennsylvania
S. Carolina Clinical Research Center
Columbia, South Carolina
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.